Clinical Inquiries

How accurate is transcutaneous bilirubin testing in newborns with darker skin tones?

Author and Disclosure Information

 

References

Stated limitations of the study included relatively low numbers of neonates with dark skin tone, no test of interobserver reliability in skin tone assignment, and enrollment of exclusively healthy neonates with low bilirubin levels.2

Other studies report overestimation in infants with darker skin tone

Two Canadian diagnostic cohort studies also found evidence that TcB testing overestimated TSB in infants with darker skin tones, although TcB test characteristics proved stable over a wide range of bilirubin levels.

The first study enrolled 451 neonates ≥ 35 weeks gestational age at a hospital in Ottawa and assessed TcB using the JM-103 meter.3 The neonates were stratified into light (n = 51), medium (n = 326), and dark (n = 74) skin tones using cosmetic reference color swatches. All had a TcB and TSB obtained within 30 minutes of each other.

The research reinforces the need for review and adjustment of transcutaneous bilirubin cut-off levels based on the local population.

TcB testing underestimated TSB in infants with light and medium skin tones and overestimated TSB in infants with darker skin tone (mean difference, –0.88 mg/dL for light; –1.1 mg/dL for medium; and 0.68 mg/dL for dark; P not given). The mean area under the curve (AUC) was ≥ 0.94 for all receiver–operator characteristic (ROC) curves across all skin tones and bilirubin thresholds (AUC range, 0-1, with > 0.8 indicating strong modeling).3

Limitations of the study included failure to check interrater reliability for skin tone assessment, low numbers of infants with elevated bilirubin (≥ 13.5 mg/dL), and very few infants in either the dark or light skin tone groups.3

Continue to: The second Canadian study...

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

Hep C, HIV coinfection tied to higher MI risk with age
MDedge Family Medicine
FDA okays terlipressin (Terlivaz) injection for hepatorenal syndrome
MDedge Family Medicine
Mentorship key to improving GI, hepatology workforce diversity
MDedge Family Medicine
New AGA guidelines advise use of antiobesity medications for weight management
MDedge Family Medicine
Low-carb diet aids weight loss in liver transplant recipients with obesity
MDedge Family Medicine
Noninvasive tests may provide prognostic value in NAFLD
MDedge Family Medicine
World falls short on HBV, HCV elimination targets
MDedge Family Medicine
Liver disease-related deaths rise during pandemic
MDedge Family Medicine
Bepirovirsen: Is a ‘functional cure’ for HBV on the horizon?
MDedge Family Medicine
Midodrine may be comparable to albumin for PICD prevention in ACLF
MDedge Family Medicine